Nov 12, 2024, 17:56
Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma
Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a recent article by Amrita Krishnan on X:
“SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (mmMRD) to direct Therapy Duration (DRAMMATIC) by Dr. Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski.”
Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski
More posts featuring Mike Thompson.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 10:01
Dec 2, 2024, 09:04
Dec 1, 2024, 22:10